A Phase 2 interventional study of Imatinib mesylate in Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST), sponsored by Novartis Pharmaceuticals. Completed at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-19.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing imatinib in Gastrointestinal Stromal Tumors — 8 open to participants now, 9 under way, 2 of them phase 3. imatinib · Gastrointestinal Stromal Tumors.
Among the 50 studies testing imatinib in Gastrointestinal Stromal Tumors, this one is the 8th largest by enrollment, is one of 3 that started in 2000, is one of 25 in phase 2, and was the 13th registered.
343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.
Browse Gastrointestinal Stromal Tumors studies →8 of the 50 studies testing imatinib in Gastrointestinal Stromal Tumors are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Kumquat Biosciences Inc. · Sites in United States
Ages 18+
University of California, San Diego · Sites in United States
Ages 18+
Reema A. Patel · Sites in United States
Ages 18+
Asan Medical Center · Sites in Korea, Republic of
Ages 20+
By country, each count listing its studies:
imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 27 · Phase 3 12 · Phase 4 3
First in 2000; this study’s year is marked. 3 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 148 is above the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.
Median enrollment 56 across the 50 interventional studies. Of the 37 that completed or were terminated, 8 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
27 studies in Gastrointestinal Stromal Tumors by Novartis: none open now, none under way, none of them phase 3. Of 26 finished, 14 (54%) have results posted.
Among the 27 studies in Gastrointestinal Stromal Tumors by Novartis, this one is the 5th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2000, is one of 13 in phase 2, and was the 3rd registered.
Novartis’s Gastrointestinal Stromal Tumors studies by the year they started, since 2000.
1 of the studies testing imatinib in Gastrointestinal Stromal Tumors that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07406633Kumquat Biosciences Inc.KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 50 studies testing imatinib in Gastrointestinal Stromal Tumors, from their registry updates:
Among Novartis’s 27 in Gastrointestinal Stromal Tumors:
This tab as a report to print or save as PDF → With an account.
In the core study, participants with unresectable or metastatic gastrointestinal stromal tumors expressing c-kit were treated with either 400 mg or 600 mg imatinib mesylate for 3 years. The 10 year extension study allowed participants, who successfully completed the core study, to continue study treatment with imatinib mesylate provided they still benefited from treatment and did not demonstrate safety concerns as per the investigator's opinion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion / exclusion criteria may have applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
400 mg once daily
Drug: Imatinib mesylate
600 mg once daily
Drug: Imatinib mesylate
Participants were randomized 1:1 to receive imatinib mesylate 400 mg/day or 600 mg/day. Upon unsatisfactory treatment effect on the starting dose of 400 mg/day or 600 mg/day imatinib mesylate, in the opinion of the treating physician, a dose increase up to 600 mg/day or 800 mg/day, was allowed provided that the participant continued to benefit from the treatment and in the absence of safety concerns.
Also known as: Glivec, Gleevec
Best Tumor Response (Core)
Best tumor response was based on the Southwestern Oncology Group (SWOG) criteria. Objective tumor response assessments were categorized according to the following criteria: complete response (CR), partial response (PR), no change or stable disease (SD), progression of disease (PD), unknown where the progression has not been documented and one or more measurable or evaluable sites have not been assessed (UNK), status after resection for progression (RP), status after resection for safety (RS), status after preventive resection (RPR), progressive after first resection (PDR) and not evaluable. Any tumor assessment after surgical resection for preventative reasons was treated like tumor assessments of UNK for calculation of best response. Tumor assessments with current objective status = RP, RS or PDR were treated like assessments with objective tumor status = PD n the calculation of best response.
Time frame: Month 36
Best Tumor Response (Core + Extension)
Best tumor response was based on the Southwestern Oncology Group (SWOG) criteria. Objective tumor response assessments were categorized according to the following criteria: complete response (CR), partial response (PR), no change or stable disease (SD), progression of disease (PD), unknown where the progression has not been documented and one or more measurable or evaluable sites have not been assessed (UNK), status after resection for progression (RP), status after resection for safety (RS), status after preventive resection (RPR), progressive after first resection (PDR) and not evaluable. Any tumor assessment after surgical resection for preventative reasons was treated like tumor assessments of UNK for calculation of best response. Tumor assessments with current objective status = RP, RS or PDR were treated like assessments with objective tumor status = PD n the calculation of best response.
Time frame: Month 156
Overall Survival (Core)
Overall survival was analyzed as time to event for all participants. Participants who did not die were censored at the last date known alive, which is the last date of any study medication, laboratory sample, tumor assessment, adverse event end date or date of last contact.
Time frame: Date of first imatinib dose to the date of death during the core period, up to 36 months.
Overall Survival (Core + Extension)
Overall survival was analyzed as time to event for all participants. Participants who did not die were censored at the last date known alive, which is the last date of any study medication, laboratory sample, tumor assessment, adverse event end date or date of last contact.
Time frame: Date of first imatinib dose to the date of death during the core and extension periods, up to 156 months.
Duration of Response (Core)
Duration of response was analyzed as time to event for all participants whose best response was at least a PR. The onset of response was the first tumor assessment that was subsequently confirmed to constitute at least a partial best response. The end of response was the first tumor assessment noting PD.
Time frame: Date of confirmed best PR or CR to date of confirmed disease progression during the core period, up to 36 months.
Duration of Response (Core + Extension)
Duration of response was analyzed as time to event for all participants whose best response was at least a PR. The onset of response was the first tumor assessment that was subsequently confirmed to constitute at least a partial best response. The end of response was the first tumor assessment noting PD.
Time frame: Date of confirmed best PR or CR to date of confirmed disease progression during the core and extension periods, up to 156 months
Progression Free Survival (PFS) (Core + Extension)
Progression free survival was analyzed as a time to event for each participant. If a participant had no event, then the PFS was censored at the last tumor assessment.
Time frame: Date of first imatinib dose to earliest date of progression, resection due to safety/progression, death due to any cause or discontinuation due to unsatisfactory therapeutic effect during the core and extension periods, up to 156 months.
Time to Treatment Failure (Core)
Time to treatment failure was analyzed as time to event for all participants. Participants who had neither progressed, died nor discontinued from the trial for any reason other than the condition no longer required therapy were censored for analysis ate the time of their last tumor assessment.
Time frame: Date of first imatinib dose to date of earliest occurrence of progression, death due to any cause, or discontinuation from the trial for any reason other than the condition no longer required therapy during the core period, up to 36 months.
Time to Treatment Failure (Core + Extension)
Time to treatment failure was analyzed as time to event for all participants. Participants who had neither progressed, died nor discontinued from the trial for any reason other than the condition no longer required therapy were censored for analysis at the time of their last tumor assessment.
Time frame: Date of first imatinib dose to date of earliest occurrence of progression, death due to any cause, or discontinuation from the trial for any reason other than the condition no longer required therapy during the core and extension periods, up to 156 month.
Time to Onset of Response (Core)
Time to response was analyzed as time to event for all participants. Participants who did not meet the definition of confirmed PR/CR were censored at the time of their last progression-free tumor assessment.
Time frame: Date of first imatinib dose to the date of the first tumor assessment that was later confirmed to be at least a partial response during the core period, up to 36 months.
Time to Onset of Response (Core + Extension)
Time to response was analyzed as time to event for all participants. Participants who did not meet the definition of confirmed PR/CR were censored at the time of their last progression-free tumor assessment.
Time frame: Date of first imatinib dose to the date of the first tumor assessment that was later confirmed to be at least a partial response during the core and extension periods, up to 156 months.
Time to Progression (Core + Extension)
Time to progression was analyzed as time to event for all participants. Participants who had neither progressed, died nor discontinued from the trial for any reason other than the condition no longer required therapy were censored for analysis at the time of their last tumor assessment.
Time frame: Date of first imatinib dose to date of progression or death due to disease indication or discontinuation due to unsatisfactory therapeutic effect during the core and extension periods, up to 156 months.
| Milestone | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg |
|---|---|---|
| Started | 74 | 74 |
| Treated participants | 73 | 74 |
| Completed | 30 | 37 |
| Not completed | 44 | 37 |
| Withdrew: Adverse event | 3 | 4 |
| Withdrew: Abnormal laboratory value | 0 | 4 |
| Withdrew: Abnormal test procedure results | 1 | 0 |
| Withdrew: Lack of efficacy | 30 | 23 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 4 |
| Withdrew: Administrative problems | 0 | 1 |
| Withdrew: Death | 4 | 0 |
| Withdrew: Determined ineligible post randomization | 1 | 0 |
| Milestone | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg |
|---|---|---|
| Started | 24 | 32 |
| Completed | 8 | 13 |
| Not completed | 16 | 19 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Abnormal laboratory value | 0 | 1 |
| Withdrew: Lack of efficacy | 9 | 14 |
| Withdrew: Condition no longer required study drug | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Administrative problems | 1 | 0 |
| Withdrew: Death | 1 | 1 |
Best tumor response was based on the Southwestern Oncology Group (SWOG) criteria. Objective tumor response assessments were categorized according to the following criteria: complete response (CR), partial response (PR), no change or stable disease (SD), progression of disease (PD), unknown where the progression has not been documented and one or more measurable or evaluable sites have not been assessed (UNK), status after resection for progression (RP), status after resection for safety (RS), status after preventive resection (RPR), progressive after first resection (PDR) and not evaluable. Any tumor assessment after surgical resection for preventative reasons was treated like tumor assessments of UNK for calculation of best response. Tumor assessments with current objective status = RP, RS or PDR were treated like assessments with objective tumor status = PD n the calculation of best response.
| participants | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg |
|---|---|---|
| Complete response | 0 | 1 |
| Partial response | 49 | 49 |
| Stable disease | 10 | 13 |
| Progressive disease | 12 | 6 |
| Not evaluable | 2 | 3 |
| Unknown | 0 | 2 |
Best tumor response was based on the Southwestern Oncology Group (SWOG) criteria. Objective tumor response assessments were categorized according to the following criteria: complete response (CR), partial response (PR), no change or stable disease (SD), progression of disease (PD), unknown where the progression has not been documented and one or more measurable or evaluable sites have not been assessed (UNK), status after resection for progression (RP), status after resection for safety (RS), status after preventive resection (RPR), progressive after first resection (PDR) and not evaluable. Any tumor assessment after surgical resection for preventative reasons was treated like tumor assessments of UNK for calculation of best response. Tumor assessments with current objective status = RP, RS or PDR were treated like assessments with objective tumor status = PD n the calculation of best response.
| participants | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg |
|---|---|---|
| Complete response | 1 | 2 |
| Partial response | 49 | 48 |
| Stable disease | 10 | 13 |
| Progressive disease | 11 | 6 |
| Not evaluable | 2 | 3 |
| Unknown | 0 | 2 |
Overall survival was analyzed as time to event for all participants. Participants who did not die were censored at the last date known alive, which is the last date of any study medication, laboratory sample, tumor assessment, adverse event end date or date of last contact.
| months | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg |
|---|---|---|
| Overall Survival (Core) | NA (NA to NA) | NA (NA to NA) |
Overall survival was analyzed as time to event for all participants. Participants who did not die were censored at the last date known alive, which is the last date of any study medication, laboratory sample, tumor assessment, adverse event end date or date of last contact.
| months | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg |
|---|---|---|
| Overall Survival (Core + Extension) | 55.9 (34.6 to 85.9) | 57.1 (43.8 to 99.7) |
Duration of response was analyzed as time to event for all participants whose best response was at least a PR. The onset of response was the first tumor assessment that was subsequently confirmed to constitute at least a partial best response. The end of response was the first tumor assessment noting PD.
| weeks | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg |
|---|---|---|
| Duration of Response (Core) | 113 (83 to NA) | 123 (79 to NA) |
Duration of response was analyzed as time to event for all participants whose best response was at least a PR. The onset of response was the first tumor assessment that was subsequently confirmed to constitute at least a partial best response. The end of response was the first tumor assessment noting PD.
| months | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg |
|---|---|---|
| Duration of Response (Core + Extension) | 27 (22 to 46) | 30 (18 to 56) |
Progression free survival was analyzed as a time to event for each participant. If a participant had no event, then the PFS was censored at the last tumor assessment.
| months | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg |
|---|---|---|
| Progression Free Survival (PFS) (Core + Extension) | 19.3 (16.4 to 28.9) | 25.2 (16.4 to 33.8) |
Time to treatment failure was analyzed as time to event for all participants. Participants who had neither progressed, died nor discontinued from the trial for any reason other than the condition no longer required therapy were censored for analysis ate the time of their last tumor assessment.
| weeks | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg |
|---|---|---|
| Time to Treatment Failure (Core) | 84 (71 to 107) | 84 (71 to 144) |
Time to treatment failure was analyzed as time to event for all participants. Participants who had neither progressed, died nor discontinued from the trial for any reason other than the condition no longer required therapy were censored for analysis at the time of their last tumor assessment.
| months | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg |
|---|---|---|
| Time to Treatment Failure (Core + Extension) | 19 (16 to 25) | 19 (16 to 33) |
Time to response was analyzed as time to event for all participants. Participants who did not meet the definition of confirmed PR/CR were censored at the time of their last progression-free tumor assessment.
| weeks | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg |
|---|---|---|
| Time to Onset of Response (Core) | 13 (12 to 24) | 12 (12 to 22) |
Time to response was analyzed as time to event for all participants. Participants who did not meet the definition of confirmed PR/CR were censored at the time of their last progression-free tumor assessment.
| months | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg |
|---|---|---|
| Time to Onset of Response (Core + Extension) | 3 (3 to 6) | 3 (3 to 3) |
Time to progression was analyzed as time to event for all participants. Participants who had neither progressed, died nor discontinued from the trial for any reason other than the condition no longer required therapy were censored for analysis at the time of their last tumor assessment.
| months | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg |
|---|---|---|
| Time to Progression (Core + Extension) | 19.8 (16.4 to 29.0) | 25.5 (16.5 to 41.5) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Imatinib Mesylate 400 mg | — | 46/73 (63%) | 72/73 (98.6%) |
| Imatinib Mesylate 600 mg | — | 40/74 (54.1%) | 73/74 (98.6%) |
| Event | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg |
|---|---|---|
| Operation NOSSurgical and medical procedures | 7/73 | 6/74 |
| Abdominal pain NOSGastrointestinal disorders | 5/73 | 3/74 |
| Anaemia NOSBlood and lymphatic system disorders | 2/73 | 4/74 |
| Gastrointestinal haemorrhage NOSGastrointestinal disorders | 3/73 | 2/74 |
| Small intestinal obstruction NOSGastrointestinal disorders | 3/73 | 2/74 |
| PyrexiaGeneral disorders | 3/73 | 2/74 |
| DehydrationMetabolism and nutrition disorders | 3/73 | 1/74 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/73 | 1/74 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/73 | 1/74 |
| NauseaGastrointestinal disorders | 2/73 | 3/74 |
| Event | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg |
|---|---|---|
| NauseaGastrointestinal disorders | 45/73 | 54/74 |
| Diarrhoea NOSGastrointestinal disorders | 43/73 | 51/74 |
| Muscle crampMusculoskeletal and connective tissue disorders | 34/73 | 43/74 |
| Periorbital oedemaSkin and subcutaneous tissue disorders | 39/73 | 39/74 |
| FatigueGeneral disorders | 35/73 | 39/74 |
| Rash NOSSkin and subcutaneous tissue disorders | 24/73 | 33/74 |
| HeadacheNervous system disorders | 22/73 | 29/74 |
| Vomiting NOSGastrointestinal disorders | 27/73 | 25/74 |
| Oedema peripheralGeneral disorders | 27/73 | 24/74 |
| Abdominal pain NOSGastrointestinal disorders | 26/73 | 25/74 |
| Age, Continuous(Years) | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg | Total |
|---|---|---|---|
| Mean | 56.6 ± 12.9 | 52.2 ± 11.12 | 54.4 ± 12.2 |
| Sex: Female, Male(Participants) | Imatinib Mesylate 400 mg | Imatinib Mesylate 600 mg | Total |
|---|---|---|---|
| Female | 29 | 35 | 64 |
| Male | 44 | 39 | 83 |
The record gives a start of Jun 2000, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imatinib
Gastrointestinal Stromal Tumors →